Events & Presentations

Events & Presentations

Take a moment to view some of our most recent events and clinical presentations.

Poster | R. James White, M.D., Ph.D., School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, at American College of Rheumatology (ACR) in Washington DC, 2016

November, 2016

Reata Pharmaceuticals presented interim data from extension phase of the LARIAT study of bardoxolone methyl in Pulmonary Arterial Hypertension at the annual meeting of the 2016 American College of Rheumatology (ACR) in Washington DC, USA. The presentation, “Bardoxolone Methyl Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study,” was presented by R. James White, M.D., Ph.D., from the School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY.

Video | Scleroderma News Interviews Colin Meyer, M.D., at Systemic Sclerosis World Conference in Lisbon, Portugal, 2016

February 19, 2016

Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, talks with Scleroderma News correspondent Dr. Ana de Barros about LARIAT, a Phase 2 study of bardoxolone methyl in patients with pulmonary hypertension (PH), and CATALYST, a Phase 3 study of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) at the 4th Systemic Sclerosis World Conference in Lisbon, Portugal, from February 18-20, 2016.

LARIAT and CATALYST

Presentation | Ronald Oudiz, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA, at CHEST 2015 in Montreal, Canada

October 27, 2015

Reata Pharmaceuticals announced initial data from the LARIAT trial evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015 American College of Chest Physicians (CHEST) in Montreal, Canada. The presentation, “Initial Data Report from ‘LARIAT’: a Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy,” was presented by Ronald Oudiz, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA. Dr. Oudiz is Director of the Pulmonary Hypertension Center and a Faculty Cardiologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Southern California.

LARIAT


Video | Panel Discussion on Friedreich’s Ataxia

September 17, 2015

Reata Pharmaceuticals’ Chief Medical Officer, Dr. Colin Meyer, discussed the MOXIe study in a panel discussion on Friedreich’s ataxia at the 7th Annual FARA-University of South Florida (USF) Health Friedreich’s Ataxia Scientific Symposium.

fara

Presentation | Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical

Officer, at the International Ataxia Research Conference 2015

March 28, 2015

Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, delivered a presentation titled, “Rationale and Design of a Clinical Study of RTA 408 in Patients with Friedreich’s Ataxia,” at the International Ataxia Research Conference 2015 in Windsor, England, co-hosted by Friedreich’s Ataxia Research Alliance (FARA) and International Ataxia Research Organizations.

fara

Video | Reata Pharmaceuticals Clinical Trial in FA for RTA 408

March 3, 2015

Reata Pharmaceuticals has launched a clinical trial in Friedreich’s ataxia (FA) for our drug RTA 408. Our Chief Medical Officer, Dr. Colin Meyer, had the opportunity to talk with the Friedreich’s Ataxia Research Alliance (FARA) about Reata and RTA 408.

fara